Vaccines

The vaccine candidate, TAK-003, is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all 4 serotypes.

Modified vaccinia Ankara vaccination showed efficacy protecting against smallpox in a phase 3 clinical trial, with fewer adverse events reported compared to the ACAM2000 vaccine group.

Study authors recommend further investigation of M72/AS01E for tuberculosis prevention and consider the trial results progress toward an efficacious vaccine.

While most influenza vaccines target the binding protein hemagglutinin, a new study shows cross-strain results for treatment and prevention focused on the glycoprotein neuraminidase.

An analysis of vaccination data among children born in 2015 and 2016 found high and stable coverage, but highlighted sociodemographic disparities in coverage.

A study of female adolescents at a health clinic in New York City has found the presence of HPV in the oral cavity is not uncommon, but the results also offer support for vaccination.

H3N2, a particularly virulent strain of influenza, blew through Australia. Is it coming to the United States this fall and winter?

A group provides an overview of ongoing research and current approaches being evaluated for the prevention of tick-borne disease.

Kindergarten vaccination coverage is near the recommended 95%, but nonexempt holdouts, which could be addressed, can still lead to outbreaks.

Using a unique approach of targeting the stalk of the hemagglutinin, investigators are taking steps toward developing a universal influenza vaccine candidate.

Millions of women and infants remain vulnerable to influenza and pertussis despite recommendations for vaccinations in pregnancy, according to a CDC report.

Reported hepatitis A vaccinations consistently fell below potentially achievable coverage between 2008 and 2017, highlighting the need for to improve simultaneous administration of childhood vaccines, according to the CDC.

The Closing Plenary of IDWeek 2019 discussed the challenges of vaccination and the optimism that we may be on the path to eradicating some global infectious diseases.

The approval marks the first FDA-approved, non-replicating smallpox vaccine, and the only FDA-approved vaccine for prevention of monkeypox.

The vaccine, manufactured by Johnson & Johnson, is administered in 2 doses, 56 days apart and will be used in areas that are not experiencing active transmission.

A National Influenza Vaccine Task Force has been established, which will develop a 5-year plan to promote new vaccine manufacturing technology and to accelerate the development of a universal flu vaccine.

Touring production called “Eureka Day” depicts parents of schoolchildren arguing both sides—but definitely has a point of view.

The target action date for the V920 investigational Ebola vaccine is set for March 14, 2020.

Being geographically close a measles outbreak could change the way individuals feel about getting vaccinated against the disease.

As the summer comes to a close, our editorial team is looking back at the top FDA approvals of 2019 to date and looking ahead at what is left on the docket this year.

Investigators with Seqirus presented findings from a handful of studies on a MF59 adjuvanted influenza vaccine at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

The crux of new information centers around the vaccine virus composition for the 2019-2020 season, and recent labeling changes for previously licensed vaccines.

The African country was to be the third participant in a pilot program that would’ve inoculated 360,000 children against the mosquito-borne virus.

Texas could be the site of the next large measles outbreak in the United States, according to a new study that highlights the low vaccination rates among schools there.

No one knows exactly why thousands of patients in dozens of states have contracted hepatitis A in recent years. In the absence of an explanation, public health officials are focusing on vaccination.